hERG & Drug-Drug Interaction Screening AssaysAvoid metabolism-related cardiac risk Most pharmaceuticals are metabolized by only a small number of liver enzymes – and one of those enzymes (CYP 3A4) processes 40% of all marketed drugs. The problem is that patients are likely to be taking multiple drugs. In such cases a drug that is safe to take alone can easily become toxic when taken with one or more other drugs that are metabolized by the same liver enzyme, because the drug will be metabolized more slowly and its concentration will build up in the bloodstream to potentially toxic levels. If the drug has a cardiac risk, the cardiac risk is greatly heightened. The classic example of the problem is the drug Seldane. Knowing your prospective drug has a cardiac risk and that it is metabolized by an overused liver enzyme is useful for guiding your discovery process and later clinical development. hERG-450™ gives you that information early in your drug-discovery process. The hERG-450™ screening assay is a service provided jointly by Apredica and ChanTest, the world's most trusted ion channel services company, and provider of an extensive catalog of ion channel testing services. hERG-450™ is available in two screening protocols. hERG-450™ Rapid Screen Contact us to learn more about hERG-450™. |
